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Abstract 
Backgrounds: In patients with cirrhosis, cystatin C (CystC) based equations may be more 
accurate indicators of glomerular filtration rate (GFR) than creatinine (Pcr) based equations. 
Renal function before liver transplantation (LT) is thought to impact survival after LT. We 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
aimed at assessing pretransplant creatinine and CystC based equations with respect to their 
predictive value on long-term survival after LT. 
Methods: From 2001 to 2011, CystC was determined at pre-LT evaluation in 682 patients 
together with GFR assessed using MDRD-4, MDRD-6, CKD-EPI-cystatin C, CKD-EPI-
creatinine, and CKD-EPI-creatinine-cystatin C equations. Patients were classified according 
to the Kidney Disease Outcomes Quality Initiative classification (KDOQI). 
Results: Median age at LT was 55[49-60] years with a median MELD score of 13.5[8.3-
19.2] and a median post-transplant follow-up of 60[26-89] months. Using CKD-EPI Cystatin 
C and the KDOQI classification, 21.1% of patients were stage 1, 43.1% stage 2, 29.1% stage 
3 and 6.5% stage 4. Kaplan Meier survival estimates was significantly different between 
KDOQI stages when determined using the CKD-EPI-CystatinC equation. This was not the 
case when using the other equations. At multivariate analysis, GFR and KDOQI estimated 
using the CKD-EPI-CystatinC equation were significantly associated with death 
(HR:0.992;CI95%:0.986-0.999 and 1.24;CI95%:1.02-1.50, respectively). When assessed 
using the MDRD-4, MDRD-6, CKD-EPI-Creatinine-CystatinC and CKD-EPI-Creatinine 
equations GFR was not significantly associated with death.  
Conclusions: Estimated pre-LT renal function is predictive of post-LT survival only when 
assessed using the CKD-EPI cystatin C equation. This supports the use of Cystatine C and of 
its related equation for the assessment of renal function before liver transplantation. 
 
Keyword: Cystatin C, creatinine, liver transplantation, glomerular filtration rate 
 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Key Point Box 
• Long term survival after liver transplantation is significantly different between 
KDOQI stages when determined using the CKD-EPI-Cystatin C equation 
• Glomerular filtration rate estimated by the CKD-EPI-Cystatin C equation is 
associated to long term survival 
• Other equations used to estimate glomerular filtration rate are not associated 
with long term survival 
• Estimating pretransplant glomerular filtration rate using the CKD-EPI-Cystatin 
C equation should improve the management of candidates for liver 
transplantation 
 
INTRODUCTION 
Renal function plays a critical role in the prognosis of patients with cirrhosis. [1] During the 
last decade, Child-Pugh score was challenged by the more efficient and objective MELD 
(Model for End-stage Liver Disease) score. [2, 3] This brought renal function, estimated by 
serum creatinine, at the foreground in the management of patients with cirrhosis, due to its 
weight in MELD score. [4] 
 
Studies showed that creatinine and creatinine-based equations are inaccurate in patients with 
cirrhosis, notably because of low muscular mass, edemas and interference of serum bilirubin 
levels with creatinine measurement. [5, 6] Recently, Francoz et al. showed that MDRD4 and 
CKD-EPI creatinine formulas significantly overestimated true GFR,[7] especially in patients 
with severe ascites. [8]  
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Serum cystatin C (CystC) synthesis is constant even in the setting of inflammation or 
neoplasm. [9, 10] Its concentration is independent of muscle mass, age and gender, and can 
be reliably determined even in case of hyperbilirubinemia. [11] 
 
In patient with cirrhosis, CystC based equations had better performance than creatinine-based 
equations to assess GFR. [12, 13] Recently, new equations to evaluate GFR based on 
standardized assays of serum creatinine and CystC (CKD-EPI creatinine and CKD-EPI 
cystatin C), or a combination of both, were reported to have improved performance in the 
estimation of GFR in patients with no liver disease. [14, 15] In cirrhotics, De Souza et al. 
showed that the CKD-EPI cystatin C equation was more accurate than other cystatin and 
creatinine-based equations in the measurement of GFR. [16]  
 
The assessment of renal function in candidates for LT has two goals: selecting patients with 
renal failure who could benefit from simultaneous liver-kidney transplantation, [7, 17] and 
determining the mortality risk of patients after LT. [18] Post-LT chronic kidney disease 
(CKD) is frequent and associated with increased mortality. [19, 20] Its main determinant is 
the presence of pretransplant CKD which may lead to post-transplant kidney failure, mainly 
when associated to the nephrotoxicity of anticalcineurin drugs and/or to other morbidities. 
[20-22] Using serum creatinine in a very large population, Nair et al. showed that 
pretransplant renal dysfunction was associated with a decrease in 2-year survival after liver 
transplantation (LT). [23]  
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A precise estimation of renal function in LT candidates should result in unveiling those 
requiring an optimized management to prevent renal failure, and identifying the long-term 
impact of renal function on post-transplant survival.  
The aim of the study was to assess the predictive value of GFR for long-term survival after 
liver transplantation when measured by reference to the new CKD-EPI equations.  
 
Patients and Methods  
Patients 
All patients who underwent LT in our center from 01/2001 to 12/2011 were included except 
in case of previous LT, multiple organ transplantation or emergency LT (lack of pretransplant 
evaluation). Cystatin C measurement is part of routine pre-LT workup in our center since 
2001.  
Combined kidney-liver transplantation was discussed in patients with estimated GFR≤30 
mL/min/1.73 m2 based on MDRD4. Patients with kidney-liver transplantation were not 
included in the study. 
The study protocol conformed to the guidelines of the declaration of Helsinki and was 
approved by the ethics committee of the University Hospital of Rennes. 
The following data were recorded: age, Body Mass Index (BMI), cause of cirrhosis, presence 
of hepatocellular carcinoma (HCC), ascites (stage 1-2-3, according to Child-Pugh score) and 
encephalopathy (stage 1-2-3, according to Child-Pugh score), routine biochemical and liver 
tests and Child-Pugh score. MELD score was available in all patients after March 2007 and 
retrospectively calculated in others when INR was available. Age and BMI of donors were 
recorded. 
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Biochemistry 
Cystatin C was prospectively assessed – at the same time and on the same blood sample as 
serum creatinine - using the Siemens N-latex-Cystatin C kit with BNII-systems. Values 
obtained before the use of the international reference material for cystatin C (ERM-
DA471/IFCC) were recalculated according to manufacturer’s recommendations (correction 
factor of 1.11). 
 
GFR was assessed according to MDRD4, MDRD-6, CKD-EPI cystatin C, CKD-EPI-
creatinine, and CKD-EPI cystatin C-creatinine equations. [15, 24, 25]  
French policies precluding the record of ethnic background, GFR was determined assuming 
all patients were non Blacks. However evaluation of patient currently on the waiting list 
(N=87) and patient who underwent LT in 2013 (N=117), showed that lower than 1% of 
patient were black. Therefore we think that it would not significantly alter estimated GFR. 
 
According to estimated GFR (eGFR) obtained from CKD-EPI-cystatin equation, patients 
were divided into the four groups of the Kidney Disease Outcomes Quality Initiative 
classification (KDOQI)[26] : stage I (normal renal function, eGFR ≥ 90 mL/min/1.73 m2), 
stage II (60≤eGFR <90mL/min/1.73 m2), stage III (30≤eGFR<60 mL/min/1.73 m2) and 
stage IV-V (eGFR<30 mL/min/1.73 m2). 
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Follow up data 
Follow up data were obtained from the local database and the National Biomedicine Agency 
(which conducts a mandatory follow-up for all transplanted patients at least once a year). 
According to French law, the corresponding database was declared to the “national 
committee of Informatics and Freedom” (CNIL, n°96-025).  
 
Patients lost to follow-up were considered dead. The main endpoint was death from any 
cause after LT. Causes of death were prospectively recorded as infections, cardio vascular 
events, cancers (including recurrence of HCC), liver-related (rejection, recurrence of initial 
liver disease), others causes, and undetermined. 
 
Statistical analysis 
Continuous data were expressed as median [first-third quartile]. Univariate analysis was 
performed using Chi square or Mann Whitney test as applicable. 
Patient survival was determined for each KDOQI-group using univariate Kaplan-Meier 
analysis. Because of the low number of KDOQI stage 4 patients (N=8 using MDRD-4), stage 
3 and 4 were merged for the Kaplan-Meier analysis.  Differences between groups were 
compared using the Log Rank test. 
Cox regression analysis was performed to assess the independent effects of pre-LT 
parameters on survival. 
Data were analyzed using 22d version of SPSS (SPSS Inc., Chicago, USA). P < 0.05 was 
considered significant with a two-tailed test.  
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RESULTS 
Patients 
During the study period, 1049 patients underwent LT, of whom 104 had previous LT, 46 
multiple-organ transplantation, and 113 emergency transplantation. Among the 786 eligible 
patients, the 682 who had cystatin C measurement available at pretransplant assessment 
constituted the study population. 
 
Clinical characteristics of the population are presented in Table 1. Median follow-up was 
60[26-89] months. 
The cause of cirrhosis was alcohol in 415 patients, chronic hepatitis C in 108, chronic 
hepatitis B in 27, chronic hepatitis D in 1, and other causes in 131. LT was performed 
because of HCC in 255 patients whose the underlying liver disease was related to alcohol 
(n=169), hepatitis C (n=45), hepatitis B (n=15), hepatitis D (n=1), non-alcoholic steato-
hepatitis (n=5), hemochromatosis (n=7) and other causes (n=13). 
 
MELD was available in 442(65%) patients. Median MELD was 13.5[8.3-19.2] in the whole 
population, 9.2[6.7-13.1] in patients with cirrhosis and associated HCC and 18.5[13.5-23.8] 
in patients without HCC. Ninety nine patients (14.5%) had a MELD score higher than 20.  
Median donor age was 49[36-62] years, median donor BMI was 24.3[21.9-27.4]kg/m2. 
Median time between evaluation and liver transplantation was 17[6-35] weeks. 
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At pretransplant assessment, median serum creatinine was 74[63-85.2]µmol/l and median 
serum cystatin C 0.99[0.85-1.20]mg/L. Median eGFR was 68.8[53.1-85.3] ml/min/1.73m² 
according to the CKD-EPI-cystatin C equation, 95.8[81-105.3]ml/min/1.73m² according to 
the CKD-EPI creatinine equation, 80.9[65.7-94.5]ml/min/1.73m² according to the CKD-EPI 
creatinine-cystatin C equation, 90.5[74.4-108.5]ml/min/1.73m² according to the MDRD-4 
equation, and106.3[85-125.9] ml/min/1.73m² according to MDRD-6. The median difference 
between eGFR according to CKD-EPI cystatin C and MDRD6 was -35.7[-50.6- -
20.9]ml/min/1.73m² 
 
Of the 682 patients, eight patients were lost to follow-up and 173 died during follow up. 
Causes of death were cancer in 57 (8.3%), infection in 35 (5.1%), cardio vascular disease in 
23 (3.4%), liver-related disorder in 18 (2.6%), others in 14 (2.1%), and undetermined in 26 
(3.8%). 
 
KDOQI groups according to estimated GFR 
Distribution and clinical characteristics of patients according to KDOQI classification using 
CKD-EPI cystatin C are presented in Table 1. 
 
Factors associated with mortality 
At univariate analysis, including all the clinical and biological variables from the donor and 
the recipient and the estimated GFR according to the different equations, serum cystatin C 
(p=0.001), donor age (p=0.005) and eGFR according to CKD-EPI cystatin C (p=0.003) and 
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CKD-EPI creatinine cystatin C (p=0.009), and the type of the underlying liver disease 
(p=0.018) were associated with an increased risk of death. 
Cox regression analysis with stratification on the causes of liver disease and adjusted for 
donor and recipient age, total bilirubin, prothrombin index, ascites stage, hepatocellular 
carcinoma and serum albumin showed that eGFR based on CKD-EPI cystatin C was the only 
variable significantly associated with death (p=0.029; HR 0.992; CI95%: 0.986-0.999) when 
introduced as a continuous variable into the model (Table 2). Similarly KDOQI stage based 
on CKD-EPI cystatin C was significantly associated with death (p = 0.025; HR 1.24; CI95% 
1.02-1.50). 
By contrast, eGFR was not significantly associated with death when calculated according to 
MDRD-4, MDRD-6, CKD-EPI creatinine-cystatin C and CKD-EPI-creatinine equations. 
 
Long term survival 
Kaplan-Meier survival estimates in the overall population at 1, 3 and 5 year were 89.6%, 
80.9% and 76% respectively.  
Figure 1 depicts survival curves of patients according to KDOQI stage using the different 
equations. 
 
Survival significantly differed according to KDOQI stages determined using CKD-EPI 
cystatin C (p=0.015). Pairwise comparison showed that survival of KDOQI stage 1 patients 
was significantly higher than KDOQI stage 2 (p=0.027) and 3-4 (p=0.003) patients. There 
was no significant difference between KDOQI stage 2 and 3-4 patients (p=0.29). 
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By contrast, survival did not significantly differed according to KDOQI stages determined 
using MDRD-4 (p=0.77), MDRD-6 (p=0.3), CKD-EPI creatinine (p=0.49), or CKD-EPI 
creatinine- cystatin C (p=0.071) equations. 
 
Regarding causes of death, using CKD EPI cystatin C equation, KDOQI stage 2 and stage 3-
4 patients had significantly higher infection related death than KDOQI stage 1 patients 
(p=0.02 and 0.03 respectively). Deaths of undetermined origin were higher in KDOQI stage 
3-4 patients (p=0.02). Others causes of deaths were not significantly different.  
 
DISCUSSION 
For the first time, the present study, based on a large number of patients with a wide range of 
liver and renal dysfunction, showed that renal function estimated using the CKD-EPI cystatin 
C equation is a prognostic factor of death after liver transplantation. By contrast creatinine-
based equations failed to be associated with long-term outcome.  
 
Mindikoglu et al. and De Souza et al. showed that cystatin C is a better marker of renal 
function in patient with cirrhosis, but they found conflicting results with respect to the more 
accurate equation to be used [16, 27]. Differences in the populations studied may explain 
these conflicting results. Mindikoglu et al. studied patients with hepatitis C-related cirrhosis 
without criteria for LT whilst De Souza et al. studied patients with end-stage alcoholic 
cirrhosis and with lower weight. Moreover sex ratios (male/female) differed markedly, which 
renders the comparison difficult, serum creatinine being lower in females than in males for a 
given GFR value. [28] However both studies concluded that cystatin C-based equations were 
more accurate than creatinine-based equations. 
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Our population was similar to that of De Souza et al.[16] with respect to age, weight, sex 
ratio (2.87 versus 2.54) and causes of liver disease, most of our patients having alcoholic 
cirrhosis (60.9%). The proportion of patients with ascites was lower when considering mild 
ascites (24% versus 42%) but similar when considering refractory ascites (22.8% versus 
17.8%). For these reasons, we extrapolated the results from De Souza et al. to our population, 
and we chose eGFR determined with CKD-EPI cystatin C equation as the reference. In 
agreement with these authors, our study shows that eGFR, is a prognostic factor of death 
when estimated using the CKD-EPI cystatin C but not the CKD-EPI creatinine cystatin C 
equation. 
 
Of note, graft allocation policy changed during the study period (March 2007) due to the 
introduction of the MELD score, which has resulted in a higher proportion of patients 
transplanted with severe liver disease. The discrepancy between estimated GFR and true GFR 
determined by gold standard is significantly correlated to the severity of liver disease and the 
presence of ascites [16, 27]. However introducing the status regarding the allocation policy 
(before or after) in our multivariate analysis did not significantly change results regarding the 
prognostic value of any of the eGFR equations (data not shown).  
 
One limitation of our study is the lack of a gold standard method to assess the true value of 
GFR. However our study aimed at assessing the clinical relevance of cystatin C as a 
prognosis tool for candidates to LT, but not the accuracy for GFR determination. Our study 
did not address the question of the most accurate method to assess renal function but it clearly 
showed that discrepancies in the prognostic value of creatinine-based and cystatin C-based 
equations were relevant. Another limitation of the study is the lack of post LT information 
regarding other disease that could influence long terme survival irrespectively of pre LT 
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GFR. The strength of our study is the large and homogenous population with a long follow-
up of patients selected for LT. 
 
With regard to the Cystatin C measurement technique, in order to reduce the variability 
between laboratories, the International Federation for Clinical Chemistry (IFCC) produced 
the reference material ERM-DA471/IFCC. [29]  This certified material promoted to reduce 
concerns generated by different calibrators, is available to manufacturers of cystatin C 
reagents since 2010. However, a recent study showed that the variability in cystatin C 
determination persisted between manufacturers of in vitro diagnosis reagents [30]. These 
variations did not have any impact on the results of our study but for future studies, special 
attention should be paid to the technique used and to the calibration traceability to the ERM-
DA471/IFCC reference material. Moreover this variability must be taken into account before 
cystatin C could be used to compare, or prioritize on the LT waiting list, patients from 
different centers. 
 
The direct correlation between pretransplant renal function and long-term mortality was 
debated for a long time. Using the sole serum creatinine, several studies concluded to 
decreased post-LT survival in case of pre-LT renal failure [31-34]. On the contrary, Brown et 
al., in a large number of patients, failed to find any impact of pre-LT renal function. [35] 
Similarly, Gonwa et al. showed that pre LT renal function has no effect on patient survival 
after LT when using creatinine-based eGFR. [36] This likely testifies of the low accuracy of 
serum creatinine determination to assess renal function. 
 
 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
The benchmark study by Nair et al. was able to demonstrate, using serum creatinine-based 
equations, that patients with impaired renal function had shorter long-term survival. [23] The 
very large population studied may have afforded the statistical power that was lacking to 
previous negative studies, and allowed for these conclusive results. It is noteworthy that our 
results based on a smaller population show that CKD-EPI-cystatin C eGFR is significantly 
associated with long term survival, suggesting a more accurate assessment of the impact of 
pretransplant renal function on survival after LT. Moreover, whereas calculated creatinine 
clearance was described as a categorical variable only in the study by Nair et al.,[23], our 
results show that CKD-EPI cystatin C eGFR is significantly associated with survival, whether 
it is considered as a categorical variable (KDOQI stage) or not. Referring to a continuous 
variable is likely to be more efficient when assessing a prognosis factor related to a 
physiological function. In their multivariate analysis, Nair et al. could assess the immediate 
and 2-year mortality, but not the 5-year mortality due to incomplete data for up to 47% of 
patient. [23] Thanks to the mandatory national follow-up in France, we had only 5 patients 
lost to follow-up and thus we were able to assess the impact of pretransplant renal function 
over the whole study period. 
 
Accordingly to previous studies of similar sample size, [35, 36] we did not found significant 
correlation between creatinine-based eGFR and long-term survival. Although it was recently 
shown to be the more accurate eGFR equation in patients with cirrhosis, [7] MDRD-6 
equation failed to show the impact of pretransplant renal function on survival after LT in our 
population. 
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Another major point is to identify the GFR threshold above which renal impairment is 
associated with increased mortality. Nair et al. considered 70mL/min/1.73 m² as normal renal 
function, and showed that patients with calculated creatinine clearance lower than 
40mL/min/1.73 m² had higher mortality. [23] More recent guidelines suggested a different 
classification and consider 90mL/min/1.73m² as the initial threshold. [37] Following these 
criteria, our results showed that even patients with mild renal impairment (KDOQI stage2: 60 
≤ eGFR < 90 mL/min/1.73 m²) had decreased long-term survival, thus emphasizing the need 
for definite evaluation of renal function. Improved identification of patient with mild renal 
impairment before LT could provide guidance for the choice of immunosuppressive regimen 
to further prevent CKD after LT. It is noteworthy that our results are based on eGFR at the 
time of evaluation for liver transplantation, therefore tailored regimen could be conveniently 
proposed at the time of evaluation. Calcineurin inhibitors sparing regimen, [38-40] and 
intensive management of CKD risks factors, [41] could be initiated earlier and be more 
efficient to reduce the prevalence of long-term chronic kidney disease. [42] 
 
The use of CKD-EPI cystatin C equation in patients with cirrhosis may lead to overestimate 
the severity of renal disease in patients with normal renal function. [16] However, we think 
that, until better marker of GFR is routinely available, overestimation of renal disease is less 
harmful than its underestimation in candidates for LT. 
 
In conclusion, we demonstrated that discrepancies between CKD-EPI cystatin C and 
creatinine - based equation are clinically relevant in patients with end-stage liver disease and 
that eGFR is predictive of long-term survival after liver transplantation if determined using 
the CKD-EPI cystatin C equation. This suggests that using cystatin C instead of creatinine to 
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assess renal function in LT candidates may allow for a more reliable detection of patients at 
risk who need optimized management before and after LT. 
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Table 1 Characteristics of study population. 
KDOQI stage was defined according to the CKD-EPI-Cystatin C equation. Ascites and 
encephalopathy stage were determined according to Child-Pugh score. Values are median 
(interquartile range) or n (%). 
KDOQI, Kidney Disease Outcomes Quality Initiative; BMI, body mass index; HCC, hepatocellular 
carcinoma; INR, international normalized ratio; MELD, model for end-stage liver disease. 
 
  All population  KDOQI 1 KDOQI 2 KDOQI 3 KDOQI 4-5 
  (N=682) (N=144) (N=294) (N=199) (N=45) 
Sex (M/F) 506/176 111/33 231/63 135/64 29/16 
Age (years) 55 [49-60] 54 [47-59] 54 [48-60] 56    [51-61] 56    [48-62] 
Associated HCC 255(37.4%) 68(47.2%) 123(41.8%) 54(27.1%) 10[22.2%) 
BMI 26.2[23.4-29.7] 25.9[23.2-29.3] 26.5[23.5-29.9] 25.9[23.4-29.7] 23.2[25.8-28.9] 
      
Donor age (years) 49[36-62] 48[35-63] 50[37-63] 49[34-61] 48[39-62] 
Donor BMI 24.3[21.9-27.5] 24.3[21.8-27.3] 24.2[21.9-27.1] 24.2[22.5-27.9] 24.9[21.9-27.6] 
      
MELD score 13.5[8.3-19.2] 9.5[6-13.3] 12.9[7.9-17.7] 15.8[11.9-21.3] 20.5[16.6-24.4] 
Meld score > 15 198(29%) 19(13.2%) 76(25.9%) 78(39.2%) 25(55.6%) 
      
Encephalopathy       
     Stage 1 562(83%) 121(84%) 256(86%) 152(76%) 33(73%) 
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     Stage 2 103(15%) 20(14%) 33(11%) 41(21%) 9(20%) 
     Stage 3 16(2%) 3(2%) 5(2%) 5(3%) 3(7%) 
 
 
      
Ascites      
     Stage 1 361(53%) 96(67%) 185(63%) 75(38%) 5(11%) 
     Stage 2 164(24%) 26(18%) 67(23%) 56(28%) 15(33%) 
     Stage 3 156(23%) 22(15%) 42(14%) 67(34%) 25(55%) 
Child score 8[5-10] 6[5-10] 7[5-10] 9[7-11] 9[8.8-11] 
      
INR 1.57[1.26-2.03] 1.37[1.17-1.79] 1.53[1.26-2] 1.72[1.36-2.21] 1.83[1.36-2.08] 
Creatinine (µmol/L) 74[63-85] 61[53-72] 71.5[63-79] 83[72-97] 142[112-165] 
Cystatin C (mg/L) 0.99[0.85-1.20] 0.73[0.68-0.78] 0.95[0.9-1.02] 1.28[1.16-1.44] 2.31[2.04-2.62] 
    
CKD-EPI-Cystatin C 
(ml/min) 68.9[53.1-85.3] 103.1[90.9-110.2] 73.6[67.3-80] 49.4[41.2-55.6] 23[18.4-26.8] 
    
Na (mmol/L) 138[134-140] 138[135-140] 138[135-140] 137[133-140] 135 [132-137] 
Cirrhosis etiology   
     Alcohol 415(60.9%) 85(59%) 167(56.8%) 131(65.8%) 32(71.1%) 
     B hepatitis 27(4%) 11(7.6%) 11(3.7%) 4(2%) 1(2.2%) 
     C hepatitis 108(15.8%) 11(7.6%) 65(22.1%) 25(12.6%) 7(15.6%) 
     Others 132(19.3%) 37(25.8%) 51(17.4%) 39(19.6%) 5(11.1%) 
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Table 2 Cox regression analysis. 
Cox regression analysis was performed with stratification according to the underlying liver disease. 
Ascites was quoted 1-2-3 according to Child-Pugh classification. Hepatocellular carcinoma was used 
as a nominal categorical variable. Hazard Ratio is in bold when significant. 
 Hazard Ratio p 95 % Confidence Interval 
Recipient Age (years) 0.998 p=0.829 0.980-1.016 
Donor Age (years) 0.994 p=0.158 0.985-1.002 
Ascites 1.020 p=0.860 0.816-1.275 
Albumin (g/L) 1.000 p=0.991 0.972-1.029 
Prothrombin Index (%) 0.994 p=0.268 0.983-1.005 
Serum Bilirubin (µmol/g) 1.000 p=0.886 0.998-1.002 
Hepatocellular Carcinoma 0.738 p=0.101 0.514-1.061 
CKD-EPI-CystC (ml/min/1.73m²) 0.992 p=0.029 0.986-0.999 
 
 
 
FIGURE LEGENDS 
Figure 1: Kaplan-Meier survival curves of patients with liver transplantation according to their 
respective KDOQI stage. Panel (A): KDOQI stage using MDRD-4. Panel (B): KDOQI stage using 
MDRD-6 Panel (C): KDOQI stage using CKD-EPI creatinine-cystatin C Panel (D): KDOQI stage 
using CKD-EPI cystatin C. 
KDOQI: Kidney Disease Outcomes Quality Initiative. CKD-EPI: chronic kidney disease 
epidemiology collaboration equation; MDRD-4: four-variable Modification of Diet in Renal Disease 
equation; MDRD-6: six-variable Modification of Diet in Renal Disease equation. 
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